Shares of Neuronetics, Inc. (NASDAQ: STIM - Get Free Report) have received a consensus recommendatio

B. Riley Securities analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ:STIM) with

MALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in inter

Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

Neuronetics NASDAQ: STIM reported second-quarter 2026 revenue growth, a sharply narrower net loss an

Neuronetics (STIM) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Esti

Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's

Neuronetics (NASDAQ:STIM) narrows FY2026 sales outlook from $160.000 million-$166.000 million to $16

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.05) per share which beat the analyst cons

MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or t

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interv

New location expands access to advanced mental health treatments while serving as Greenbrook's flags

MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interv

Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroSta

MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interv

BTIG initiated coverage of Neuronetics Inc. (NASDAQ:STIM) on Monday, noting that the company is ente

BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. R

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's

BTIG analyst Sam Eiber initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and anno

Neuronetics is revisited following prior coverage in March 2026. The article focuses on STIM's recen

MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interv

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technolo

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technolo

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technolog

Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript

Neuronetics (STIM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Esti

Business OutlookFor the second quarter of 2026, the Company expects total revenue growth in the mid-

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.16) per share which beat the analyst cons

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “N

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stag

This week's deal activity spans gaming, healthcare, energy, and private equity, with activist sa

On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by m

Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on des

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and low

Neuronetics (NASDAQ:STIM) sees FY2026 sales of $160.000 million-$166.000 million vs $164.167 million

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.10) per share which beat the analyst cons

Neuronetics shares jumped 41% in after-hours trading following strong preliminary fourth-quarter 202

Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integ